Shots: AbCellera to receive technology access fee, milestones and royalties on the development and commercialization of pre-cliniocal candidates & will develop Abs for Denali’s eight targets for neurological disorders On 12 Jun,2018 Denali therapeutics collaborated with AbCellera for its single-cell technology to develop hundreds of mAbs for neurodegenerative diseases AbCellera’s single-cell screening technology is a […]Read More
Shots: Novartis to get minority equity in Anthos and will grant rights to Anthos for MAA868 to develop in CVD. Blackstone Life Sciences to fund the joint venture with $250M and will take care of development of all products The focus of the agreement is to build a joint venture i.e Anthos Therapeutics developing anti-thrombotic […]Read More
Shots: Novartis & Target PharmaSolutions collaborates for the onset of global TARGET-DERM study evaluating adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs) The initial focus of the collaboration is to develop therapies & expand Novartis’ footprints in immune-dermatology for atopic dermatitis (eczema) with further expansion to hidradenitis suppurativa (painful bumps under the skin), […]Read More
Shots: The approval is based on P-III study results assessing Tremfya (guselkumab, 100mg) vs PBO in 78 patients with moderate-to-severe plaque psoriasis P-III ORION study: IGA score of 0/1 or PASI 90 @16wks. (81%, 76% vs 0%,0%); IGA score of 0 @16 wk (56% vs 0%); PASI 100 response @16 wks (50% vs 0%) Tremfya […]Read More
Shots: The expanded label approval is based on P-III DERIVE study results assessing Farxiga (dapagliflozin 10 mg) vs PBO in patients with type 2 diabetes (T2D) with moderate renal impairment P-III DERIVE study results: reduction in HbA1c with safe results (-0.37% vs -0.03%), reduced mean body weight (-3.17kg vs -1.92kg), reduced mean fasting plasma glucose […]Read More
Shots: Sarepta exercises its option to acquire Myonexus Therapeutics, in all stock transaction for $165M with its five Limb-girdle muscular dystrophy (LGMDs) gene therapies programs i.e LGMD2E, LGMD2D, LGMD2B, LGMD2L & LGMD2C In May,2018 Sarepta and Myonexus collaborated to develop and advance multiple gene therapy programs for LGMD, paying $60M upfront & milestones, gaining excsluive […]Read More
Shots: The expanded indication approval is based on PERSPECTIVE Study assessing 183 patients with older-generation Resolute Integrity DES The study resulted in low rates of repeat revascularization 1.1%, cardiac death 2.2%, minimal stent thrombosis 0.06% and safe results Resolute Drug-Eluting Stent (DES) platform includes Resolute Onyx and Resolute Integrity DES targeted for the treatment of […]Read More
Shots: TetraGenetics to receive $25M upfront, $248M milestones as contingent payments, FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with an option to develop therapies post IND submission for pain and autoimmune disorders The focus of the agreement is to develop non-opioid therapies with advancement […]Read More
Shots: The companies enter into a clinical research collaboration for the evaluation of efficacy and safety of immunotherapy combining Roche’s Tecentriq (atezolizumab) with Immatics’ IMA101 in solid tumors In H2’19, companies plan for the onset of the trial based on ACTolog IMA101-101 study protocol at MD Anderson Cancer Center to kill cancer cells by blocking […]Read More
Shots: The P-III POLO study involves assessing of Lynparza (olaparib, 300mg, bid) vs PBO in 154 patients in ratio (3:2) with BRCAm metastatic pancreatic cancer whose disease had not progressed on 1st-line Pt-based CT The P-III POLO study results: improvement in PFS (7.4 vs 3.8mos.); @1yr & 2yrs. no disease progression ( 34% & 22% […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
